Jermendy György
III. Belgyógyászati Osztály.
Orv Hetil. 2006 Nov 19;147(46):2223-6.
The use of insulin pump treatment (CSII: continuous subcutaneous insulin infusion) became widely accepted in the last couple of years. A growing body of experiences accumulated in paediatric practice because CSII is preferable for treating young patients with type 1 diabetes. Nevertheless, CSII can be used, if indicated, for treating type 2 diabetic patients as well. Recently, fast acting insulin analogues are exclusively used for CSII. At moment, clinical observations with insulin lispro and insulin aspart are available but experiences with glulisine are still limited. Although some inconsistencies could be observed in the literature, it is widely accepted, that higher reduction in HbA(1c) values could be achieved by CSII as compared to intensive conservative insulin treatment; this could be more pronounced in cases with high initial HbA(1c) values. CSII with short acting insulin analogues could lead to a higher reduction of HbA(1c) values than CSII with human regular insulin. Moreover, the decrease of hypoglycaemic events could be expected in some cases.
在过去几年中，胰岛素泵治疗（持续皮下胰岛素输注，CSII）已被广泛接受。由于CSII更适合治疗1型糖尿病的年轻患者，儿科实践中积累的经验越来越多。然而，如果有指征，CSII也可用于治疗2型糖尿病患者。目前，速效胰岛素类似物专门用于CSII。目前有关于赖脯胰岛素和门冬胰岛素的临床观察，但关于谷赖胰岛素的经验仍然有限。尽管在文献中可以观察到一些不一致之处，但人们普遍认为，与强化保守胰岛素治疗相比，CSII可以使糖化血红蛋白（HbA1c）值有更大幅度的降低；在初始HbA1c值较高的情况下，这种情况可能更明显。与使用人常规胰岛素的CSII相比，使用短效胰岛素类似物的CSII可能会使HbA1c值有更大幅度的降低。此外，在某些情况下，可以预期低血糖事件会减少。
